Kabi Introduces Idacio Into Crowded German Adalimumab Market
Fresenius Kabi is entering a German adalimumab market in which Amgen, Mylan and Sandoz are already competing against AbbVie’s Humira reference brand. In this environment, Fresenius’ sales expectations are modest.
You may also be interested in...
EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.
Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.
As a late entrant to the European adalimumab market, Fresenius is cooling expectations for sales of its Idacio biosimilar while it continues work on late-stage candidates pegfilgrastim and tocilizumab.